Fate Therapeutics, Inc. (FATE)
1.28
-0.06
(-4.48%)
USD |
NASDAQ |
Nov 13, 16:00
1.275
0.00 (0.00%)
After-Hours: 19:59
Fate Therapeutics Enterprise Value : 90.93M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 90.93M |
| November 12, 2026 | 98.22M |
| November 11, 2026 | 130.43M |
| November 10, 2026 | 150.48M |
| November 09, 2026 | 171.14M |
| November 06, 2026 | 158.38M |
| November 05, 2026 | 160.20M |
| November 04, 2026 | 189.37M |
| November 03, 2026 | 183.29M |
| November 02, 2026 | 179.65M |
| October 30, 2026 | 188.15M |
| October 29, 2026 | 199.09M |
| October 28, 2026 | 199.09M |
| October 27, 2026 | 186.94M |
| October 26, 2026 | 185.12M |
| October 23, 2026 | 191.80M |
| October 22, 2026 | 189.37M |
| October 21, 2026 | 186.94M |
| October 20, 2026 | 185.72M |
| October 19, 2026 | 161.42M |
| October 16, 2026 | 152.91M |
| October 15, 2026 | 169.32M |
| October 14, 2026 | 171.14M |
| October 13, 2026 | 178.43M |
| October 12, 2026 | 194.23M |
| Date | Value |
|---|---|
| October 09, 2026 | 200.31M |
| October 08, 2026 | 194.23M |
| October 07, 2026 | 196.66M |
| October 06, 2026 | 213.68M |
| October 05, 2026 | 230.69M |
| October 02, 2026 | 217.32M |
| October 01, 2026 | 214.89M |
| September 30, 2026 | 223.40M |
| September 29, 2026 | 199.64M |
| September 28, 2026 | 199.64M |
| September 25, 2026 | 196.14M |
| September 24, 2026 | 193.81M |
| September 23, 2026 | 205.47M |
| September 22, 2026 | 222.98M |
| September 21, 2026 | 217.14M |
| September 18, 2026 | 217.14M |
| September 17, 2026 | 215.98M |
| September 16, 2026 | 206.64M |
| September 15, 2026 | 196.14M |
| September 14, 2026 | 194.97M |
| September 11, 2026 | 191.47M |
| September 10, 2026 | 193.81M |
| September 09, 2026 | 206.64M |
| September 08, 2026 | 213.64M |
| September 04, 2026 | 211.31M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AVITA Medical, Inc. | 520.58M |
| Agenus, Inc. | 487.93M |
| Amgen, Inc. | 292.70B |
| Anika Therapeutics, Inc. | 160.67M |
| BioCryst Pharmaceuticals, Inc. | 2.402B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -30.69M |
| Total Expenses (Quarterly) | 30.69M |
| EPS Diluted (Quarterly) | -0.2482 |
| Earnings Yield | -80.48% |
| Normalized Earnings Yield | -80.31 |